OK here is some info and some resources for HCG....

Pregnyl (Human Chorionic Gonadotropin)

HCG - human chorionic gonadotropin - - Human Chorionic Gonadotropin Use After Anabolic Steroid Cycles for Bodybuilding

Human Chorionic Gonadotropin (HCG - human chorionic gonadotropin - ) is a peptide hormone that mimics the action of luteinizing hormone (lh - leutenizing hormone - ). lh - leutenizing hormone - is the hormone that stimulates the testes to produce testosterone. (1) More specifically lh - leutenizing hormone - is the primary signal sent from the pituitary to the testes, which stimulates the leydig cells within the testes to produce testosterone.

When steroids are administered, lh - leutenizing hormone - levels rapidly decline. The absence of an lh - leutenizing hormone - signal from the pituitary causes the testes to stop producing testosterone, which causes rapid onset of testicular degeneration. The testicular degeneration begins with a reduction of leydig cell volume, and is then followed by rapid reductions in intra-testicular testosterone (ITT), peroxisomes, and Insulin-like factor 3 (INSL3) – All important bio-markers and factors for proper testicular function and testosterone production. (2-6,19) However, this degeneration can be prevented by a small maintenance dose of HCG - human chorionic gonadotropin - ran throughout the cycle. Unfortunately, most steroid users have been engrained to believe that HCG - human chorionic gonadotropin - should be used after a cycle, during PCT. Upon reviewing the science and basic endocrinology you will see that a faster and more complete recovery is possible if HCG - human chorionic gonadotropin - is ran during a cycle.

Firstly, we must understand the clinical history of HCG - human chorionic gonadotropin - to understand its purpose and its most efficient application. Many por “steroid profiles” advocate using HCG - human chorionic gonadotropin - at a dose of 2500-5000iu once or twice a week. These were the kind of dosages used in the historical (1960’s) HCG - human chorionic gonadotropin - studies for hypogonadal men who had reduced testicular sensitivity due to prolonged lh - leutenizing hormone - deficiency. (21,22) A prolonged lh - leutenizing hormone - deficiency causes the testes to desensitize, requiring a higher HCG - human chorionic gonadotropin - dose for ample stimulation. In men with normal lh - leutenizing hormone - levels and normal testicular sensitivity, the maximum increase of testosterone is seen from a dose of only 250iu, with minimal increases obtained from 500iu or even 5000iu. (2,11) (It appears the testes maximum secretion of testosterone is about 140% above their normal capacity.) (12-18) If you have allowed your testes to desensitize over the length of a typical steroid cycle, (8-16 weeks) then you would require a higher dose to elicit a response in an attempt to restore normal testicular size and function – but there is cost to this, and a high probability that you won’t regain full testicular function.

One term that is critical to understand is testosterone secretion capacity which is synonymous to testicular sensitivity. This is the amount of testosterone your testes can produce from any given lh - leutenizing hormone - or HCG - human chorionic gonadotropin - stimulation. Therefore, if you have reduced testosterone secretion capacity (reduced testicular sensitivity), it will take more lh - leutenizing hormone - or HCG - human chorionic gonadotropin - stimulation to produce the same result as if you had normal testosterone secretion capacity. If you reduce your testosterone secretion capacity too much, then no amount of lh - leutenizing hormone - or HCG - human chorionic gonadotropin - stimulation will trigger normal testosterone production – and this leads to permanently reduced testosterone production.

Buy HCG - human chorionic gonadotropin -

To get an idea of how quickly you can reduce your testosterone secretion capacity from your average steroid cycle, consider this: lh - leutenizing hormone - levels are rapidly decreased by the 2nd day of steroid administration. (2,9,10) By shutting down the lh - leutenizing hormone - signal and allowing the testis to be non-functional over a 12-16 week period, leydig cell volume decreases 90%, ITT decreases 94%, INSL3 decreases 95%, while the capacity to secrete testosterone decreases as much as 98%. (2-6)

Note: visually analyzing testes size is a poor method of judging your actual testicular function, since testicular size is not directly related to the ability to secrete testosterone. (4) This is because the leydig cells, which are the primary sites of testosterone secretion, only make up about 10% of the total testicular volume. Therefore, when the testes may only appear 5-10% smaller, the testes ability to secrete testosterone upon lh - leutenizing hormone - or HCG - human chorionic gonadotropin - stimulation can actually be significantly reduced to 98% of their normal production. (3-5) The point here is to not judge testosterone secretion capacity by testicular size.
HCG - human chorionic gonadotropin -

The decreased testosterone secretion capacity caused by steroid use was well demonstrated in a study on power athletes who used steroids for 16 weeks, and were then administered 4500iu HCG - human chorionic gonadotropin - post cycle. It was found that the steroid users were about 20 times less responsive to HCG - human chorionic gonadotropin - , when compared to normal men who did not use steroids. (8) In other words, their testosterone secretion capacity was dramatically reduced because they did not receive an lh - leutenizing hormone - signal for 16 weeks. The testes essentially became desensitized and crippled. Case studies with steroid using patients show that aggressive long-term treatment with HCG - human chorionic gonadotropin - at dosages as high as 10,000iu E3D for 12 weeks were unable to return full testicular size. (7) Another study with men using low dose steroids for 6 weeks showed unsuccessful return of Insulin-like factor-3 (INSL3) concentration in the testes upon 5000iu/wk of HCG - human chorionic gonadotropin - treatment for 12 weeks (6) (INSL3 is an important biomarker for testosterone production potential and sperm production. 20)

Buy HCG - human chorionic gonadotropin -

These studies show that postponing HCG - human chorionic gonadotropin - usage until the end of a steroid cycle increases your need for a higher dose of HCG - human chorionic gonadotropin - , and decreases your odds of a full recovery. As a consequence to using a higher dose of HCG - human chorionic gonadotropin - at the end of a cycle, estrogen will be increased disproportionately to testosterone, which then causes further hpta - hypothalamic-pituitary-testicular axis - suppression (from high estrogen) while increasing the risk of gynecomastia. (11) For example, high doses of HCG - human chorionic gonadotropin - have been found to raise estradiol up to 165%, while only raising testosterone 140%. (11) Higher doses of HCG - human chorionic gonadotropin - are also known to reduce lh - leutenizing hormone - receptor concentration and degrade the enzymes responsible for testosterone synthesis within the testes (12,13,19 ) -- the last thing someone wants during recovery. While these negative effects of HCG - human chorionic gonadotropin - can be partly mitigated by the use of a selective estrogen receptor modulator such as tamoxifen, it will create further problems associated with using a toxic selective estrogen receptor modulator (covered in another article).

In light of the above evidence, it becomes obvious that we must take preventative measures to avoid this testicular degeneration. We must protect our testicular sensitivity. Besides, with HCG - human chorionic gonadotropin - being so readily available, and such a painless shot, it makes you wonder why anyone wouldn’t use it on cycle.

Based on studies with normal men using steroids, 100iu HCG - human chorionic gonadotropin - administered everyday was enough to preserve full testicular function and ITT levels, without causing desensitization typically associated with higher doses of HCG - human chorionic gonadotropin - . (2) It is important that low-dose HCG - human chorionic gonadotropin - is started before testicular sensitivity is reduced, which appears to rapidly manifest within the first 2-3 weeks of steroid use. Also, it’s important to discontinue the HCG - human chorionic gonadotropin - before you start PCT so your leydig cells are given a chance to re-sensitize to your body’s own lh - leutenizing hormone - production. (To help further enhance testicular sensitivity, the dietary supplement Toco-8 may be used)

A more convenient alternative to the above recommendation would be a twice a week shot of 200iu HCG - human chorionic gonadotropin - , or possibly a once a week shot of 500iu. However, it is most desirable to adhere to a lower more frequent dose of HCG - human chorionic gonadotropin - to mimic the body’s natural lh - leutenizing hormone - release and minimize estrogen conversion. If you are starting HCG - human chorionic gonadotropin - late in the cycle, one could calculate a rough estimate for their required HCG - human chorionic gonadotropin - ‘kick starting’ dosage by multiplying 40iu x days of lh - leutenizing hormone - absence, since the testes will be desensitized, thus requiring a higher dose. (ie. 40iu x 60 days = 2400iu HCG - human chorionic gonadotropin - dose)

Discuss HCG - human chorionic gonadotropin - on the EliteFitness.com Forums:

Instead of anabolic steroids, could one do an HCG - human chorionic gonadotropin - cycle?

is HCG - human chorionic gonadotropin - illegal?

can you stack HCG - human chorionic gonadotropin - with sustanon

mixing HCG - human chorionic gonadotropin - for PCT

Fake organon HCG - human chorionic gonadotropin - ?

HCG - human chorionic gonadotropin - storage?

HCG - human chorionic gonadotropin - : 10 days straight vs. 3x/wk for 3 weeks

Can i get away with PCT without HCG - human chorionic gonadotropin - ?

Trying to figure out if I should do HCG - human chorionic gonadotropin - ...and when

would u use vet HCG - human chorionic gonadotropin - ?

HCG - human chorionic gonadotropin - /pregnyl

Advice with Finaplix - trenbolone acetate - , Sustanon, Clomid and HCG - human chorionic gonadotropin -

How to prepare HCG - human chorionic gonadotropin - ? Vial in Water , Vial in Powder? Help

Note: If following the on cycle HCG - human chorionic gonadotropin - protocol, HCG - human chorionic gonadotropin - should NOT be used for PCT.

Recap:

For preservation of testicular sensitivity, use 100iu HCG - human chorionic gonadotropin - ED starting 7 days after your first anabolic steroids dose. At the end of the cycle, drop the HCG - human chorionic gonadotropin - two weeks before the anabolic steroids clear the system. For example, you would drop HCG - human chorionic gonadotropin - about the same time as your last Testosterone Enanthate shot. Or, if you are ending the cycle with orals, you would drop the HCG - human chorionic gonadotropin - about 10 days before your last oral dose. This will allow for a sudden and even clearance in hormone levels, while initiating lh - leutenizing hormone - and FSH - follicle stimulating hormone - production from the pituitary, to begin stimulating your testes to produce testosterone. Remember, recovery doesn’t begin until you are off HCG - human chorionic gonadotropin - since your body will not release its own lh - leutenizing hormone - until the HCG - human chorionic gonadotropin - has cleared the system.

In conclusion, we have learned that utilizing HCG - human chorionic gonadotropin - during a steroid cycle will significantly prevent testicular degeneration. This helps create a seamless transition from “on cycle” to “off cycle” thus avoiding the post cycle crash.

Pregnyl, Profasi, Human Chorionic Gonadotropin, HCG - human chorionic gonadotropin - , HCG - human chorionic gonadotropin - Lepori, Gonadotraphon, Choron, Chorigon, Cx, Choragon, H.C.G
"SOURCE!!!

http://www.elitefitness.com/forum/life-extension-andropause-masters-body...

PACKAGE INSERT

Novarel
®

(Chorionic Gonadotropin for Injection, USP) FOR INTRAMUSCULAR USE ONLY
Rx Only
DESCRIPTION: Human chorionic gonadotropin (HCG), a polypeptide hormone produced by the human
placenta, is composed of an alpha and a beta sub-unit. The alpha sub-unit is essentially identical
to the alpha sub-units of the human pituitary gonadotropins, luteinizing hormone (LH) and
follicle-stimulating hormone (FSH), as well as to the alpha sub-unit of human thyroid-stimulating
hormone (TSH). The beta sub-units of these hormones differ in amino acid sequence.

Chorionic Gonadotropin is a water soluble glycoprotein derived from human pregnancy urine. The
sterile lyophilized powder is stable. When reconstituted with Bacteriostatic Water for Injection
preserved with benzyl alcohol 0.9%, the solution should be refrigerated and used within 30 days.

Each vial contains:
Chorionic Gonadotropin 10,000 USP Units, Mannitol 100 mg, Dibasic Sodium
Phosphate 16 mg, and Monobasic Sodium Phosphate 4 mg.

CLINICAL PHARMACOLOGY: The action of HCG is virtually identical to that of pituitary LH, although
HCG appears to have a small degree of FSH activity as well. It stimulates production of gonadal
steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce
androgens and the corpus luteum of the ovary to produce progesterone. Androgen stimulation in the
male leads to the development of secondary sex characteristics and may stimulate testicular descent
when no anatomical impediment to descent is present. This descent is usually reversible when HCG is
discontinued. During the normal menstrual cycle, LH participates with FSH in the development and
maturation of the normal ovarian follicle, and the mid-cycle LH surge triggers ovulation. HCG can
substitute for LH in this function.

During a normal pregnancy, HCG secreted by the placenta maintains the corpus luteum after LH
secretion decreases, supporting continued secretion of estrogen and progesterone, and preventing
menstruation. HCG HAS NO KNOWN EFFECT ON FAT MOBILIZATION, APPETITE OR SENSE OF HUNGER, OR BODY FAT
DISTRIBUTION.

INDICATIONS AND USAGE: HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE
TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT
RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR “NORMAL”
DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH
CALORIE-RESTRICTED DIETS.

1. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce
   testicular descent in situations when descent would have occurred at puberty. HCG thus may help to
   predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent
   following HCG administration is permanent, in most cases the response is temporary. Therapy is
   usually instituted between the ages of 4 and 9.
2. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary
   deficiency) in males.
3. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of
   anovulation is secondary and not due to primary ovarian failure, and who has been appropriately
   pretreated with human menotropins.

CONTRAINDICATIONS: Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm,
prior allergic reaction to HCG. HCG may cause fetal harm when administered to a pregnant woman.
Combined HCG/PMS (pregnant mare’s serum) therapy has been noted to induce high incidences of
external congenital anomalies in the offspring of mice, in a dose-dependent manner. The potential
extrapolation to humans has not been determined.

WARNINGS: HCG should be used in conjunction with human menopausal gonadotropins only by physicians
experienced with infertility problems who are familiar with the criteria for patient selection,
contraindications, warnings, precautions, and adverse reactions described in the package insert for
menotropins. The principal serious adverse reactions during this use are: (1) Ovarian
hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain, and/or
pleural effusion; (2) Enlargement of preexisting ovarian cysts or rupture of ovarian cysts with
resultant hemoperitoneum; (3) Multiple births, and (4) Arterial thromboembolism.

The recommended diluent for reconstitution is Bacteriostatic Water for Injection preserved with
benzyl alcohol 0.9%. Benzyl alcohol has been reported to be associated with a fatal “Gasping
Syndrome” in premature infants.

PRECAUTIONS: General: 1. Induction of androgen secretion by HCG may induce precocious
puberty in patients treated for cryptorchidism. Therapy should be discontinued if signs of
precocious puberty occur.

2. Since androgens may cause fluid retention, HCG should be used with caution in patients with
   cardiac or renal disease, epilepsy, migraine, or asthma.

Drug/Laboratory test: HCG can crossreact in the radioimmunoassay of gonadotropins, especially
luteinizing hormone. Each individual laboratory should establish the degree of
crossreactivity with their gonadotropin assay.
Physicians should make the laboratory aware of patients on HCG if gonadotropin
levels are requested.

Carcinogenesis, Mutagenesis, Impairment of Fertility: There have been sporadic reports of
testicular tumors in otherwise healthy young men receiving HCG for secondary infertility. A
causative relationship between HCG and tumor development in these men has not been established.
Defects of forelimbs and of the central nervous system, as well as alterations in sex ratio, have
been reported in mice on combined gonadotropin and HCG regimens. The dose of gonadotropin used was
intended to induce superovulation. No mutagenic effect has been clearly established in humans.
Fertility—see “Indications and Usage.”

Pregnancy: Teratogenic Effects--Category X: See “Contraindications” section. Combined HCG/PMS
(pregnant mare’s serum) therapy has been noted to induce high incidences of external congenital
anomalies in the offspring of mice, in a dose-dependent manner. The potential extrapolation to
humans has not been determined.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs
are excreted in human milk, caution should be exercised when HCG is administered to a nursing
woman.

Pediatric Use: Safety and effectiveness in children below the age of 4 have not been established.

ADVERSE REACTIONS: (See WARNINGS) Headache, irritability, restlessness, depression, fatigue, edema,
precocious puberty, gynecomastia, pain at the site of injection. Hypersensitivity reactions both
localized and systemic in nature, including erythema, urticaria, rash, an-gioedema, dyspnea and
shortness of breath, have been reported. The relationship of these allergic-like events to the
polypeptide hormone or the diluent containing benzyl alcohol is not clear.

DOSAGE AND ADMINISTRATION: (Intramuscular Use Only): The dosage regimen employed in any
particular case will depend upon the indication for use, the age and weight of the patient, and the
physician’s preference. The following regimens have been advocated by various authorities.
Prepubertal cryptorchidism not due to anatomical obstruction: (1) 4,000 USP Units three times
weekly for three weeks.
(2) 5,000 USP Units every second day for four injections.
(3) 15 injections of 500 to 1,000 USP Units over a period of six weeks.
(4) 500 USP Units three times weekly for four to six weeks. If this course of treatment is not
successful, another is begun one month later, giving 1,000
USP Units per injection.

Selected cases of hypogonadotropic hypogonadism in males:
(1) 500 to 1,000 USP Units three times a week for three weeks, followed by the same dose twice
a week for three weeks.
(2) 4,000 USP Units three times weekly for six to nine months, following which the dosage may
be reduced to 2,000 USP Units three times weekly for an
additional three months.

Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of
anovulation is secondary and not due to primary ovarian failure and who has been appropriately
pre-treated with human menotropins (See prescribing information for menotropins for dosage and
administration for that drug product).

5,000 to 10,000 USP Units one day following the last dose of menotropins. (A
dosage of 10,000 USP Units is recommended in the labeling for menotropins).

Parenteral drug products should be inspected visually for particulate matter and discoloration
prior to administration, whenever solution and container permit.

HOW SUPPLIED: Chorionic Gonadotropin for Injection, USP, is available as individually packaged
vials containing 10,000 USP Units per vial (NDC 55566-
1501-0).

Store dry product at 20°-25°C (68°-77°F), excursions permitted between 15° and
30°C (between 59° and 86°F) [See USP Controlled Room Temperature].

AFTER RECONSTITUTION WITH BACTERIOSTATIC WATER FOR INJECTION PRESERVED WITH BENZYL ALCOHOL 0.9%,
REFRIGERATE THE PRODUCT AT 2°-8°C (36°-46°F) AND USE WITHIN 30 DAYS.

Mfd. for:
Ferring Pharmaceuticals Inc. Parsippany, NJ 07054

Mfd. by:
DRAXIS Specialty Pharmaceuticals Inc.
DRAXIS Specialty
Quebec, Canada